Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
2. Components and design of Chimeric Antigen Receptors (CARs)
3. scFv cloning, vectors and CAR production in laboratory for preclinical application
4. Production of CAR-T cells for clinical application
5. Challenges and opportunities to improve CAR-TE cell therapy
Dr. Mumtaz Balkhi brings dual backgrounds in cancer biology and immunotherapeutics to a research program in translational research. With a Ph.D. in Human Biology, he applies molecular biology techniques and utilizes his knowledge of molecular and cellular immunology to develop new gene therapies to improve immunotherapies against cancer. He has more than 20 publications in highly reputable journals including Science and Cell Press Journals. His 2013 publication in Science Signaling Journal featured as Cover Story and his latest publication in Cell Press journal was recently highlighted in Cell Press Crosstalk. Dr. Balkhi hopes to establish a Chimeric Antigen Receptor (CAR) Immunotherapy program. He is trained in this field and had an opportunity to drive and lead projects related to CAR Immunotherapy.